Hypoparathyroidism
3 competing products in clinical development for Hypoparathyroidism.
Pipeline by Phase
Phase 11
Phase 22
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| 400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection | MBX Biosciences | Phase 2 | Active | 33 |
| MBX 2109 | MBX Biosciences | Phase 2 | Completed | 29 |
| PCO371 + Placebo | Chugai Pharmaceutical | Phase 1 | Terminated | 21 |